Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Metabolomische en darmmicrobiële biomarkers van het stoppen met roken bij het stoppen met roken bij langdurige medicamenteuze therapie: een gerandomiseerde gecontroleerde studie

28 september 2026 bijgewerkt door: Sigmund Freud PrivatUniversitat

Theoretical Framework: Cigarette smoking is the leading preventable cause of death worldwide, with nicotine dependence notably common among individuals with Substance Use Disorders (SUD). Smoking exacerbates both physical and mental health issues, further complicating the treatment of SUD. Current therapeutic approaches for SUD often prove inadequate, indicating a need for new strategies. Recent advancements in metabolomics and gut microbiome research have provided valuable insights into the biological mechanisms underlying addiction.

Objectives: This study aims to investigate the therapeutic potential of smoking cessation for individuals with SUD, using a six-week intervention within a therapeutic community. The research specifically explores the psychobehavioral, metabolic, and gut microbiome domains. It is hypothesized that smoking cessation will improve emotional regulation, self-efficacy, and reduce substance craving, mediated by changes in metabolic and microbiome profiles linked to brain reward systems.

Methods: A randomized controlled trial (N=150) will be conducted, examining outcomes such as clinical relapse rates, microbial and metabolic markers, particularly in choline and folate metabolism. Participants with SUD (n=100) will undergo a six-week smoking cessation intervention, with pre- and post-assessments, compared to a control group receiving treatment as usual. Metabolomic and microbiome analyses will be conducted using blood and stool samples, alongside psychological assessments via questionnaires. Assessments on a behavioural level will take place at a 3-months follow-up.

A cross-sectional, non-interventional healthy control group (n=50) will be examined at a single timepoint with an anologous panel of psychological variables, blood and stool to ascertain differences between smokers with SUD and healthy controls.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

97

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Fehring, Oostenrijk, 8350
        • Grüner Kreis Organization Johnsdorf Facility
      • Graz, Oostenrijk, 8036
        • Medical University Graz
      • Vienna, Oostenrijk, 1020
        • Sigmund Freud Private University Vienna

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • diagnosis of a form of substance use disorder (F1x.x) by a licensed psychiatrist according to ICD-10
  • minimum age of 18 years
  • sufficient knowledge of the German language
  • willingness to quit smoking
  • willingness and ability to consent

Inclusion criteria for healthy controls :

  • minimum age of 18 years
  • sufficient knowledge of the German language
  • willingness and ability to consent

Exclusion Criteria:

  • lack of consent, inability to provide informed consent
  • age below 18,
  • acute psychotic symptoms or acute suicidal tendencies
  • cardiovascular disease
  • pregnancy or breastfeeding
  • severe mental or organic illnesses (such as epilepsy, brain tumors, recent major surgery), tumor diseases, dementia (Mini Mental Score <20), severe autoimmune diseases or immunosuppression, acute infections, or acute diarrhea, prior gastrointestinal surgery (except appendectomy)
  • probiotic intake within the last 6 months,
  • ongoing consumtion of dietary supplements, probiotics, antibiotics, or prebiotic supplements during the study
  • prior participation in a smoking cessation programme

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Treatment As Usual

Patients in the TAU group receive long-term rehabilitation drug treatment according to the 'community as a treatment'-model

The standard treatment within the 'Grüner Kreis' therapeutic community - which all participants will receive - consists of group therapy (once a week), individual psychotherapy (once a week), counselling by social workers, psychiatric consultations, as well as sport-, art- and work-therapy. Daily life is organized according to principles of therapeutic community-based addiction treatment.

Experimenteel: 6-weeks smoking cessation cognitive-behavioral therapy intervention

The "smoke free in 6 weeks" program is a standardized behavioural therapy intervention that takes place once a week for 1.5 hours over 6 weeks and is provided by the Austrian health insurance provider Österreichische Gesundheitskasse (ÖGK).

The standard treatment within the 'Grüner Kreis' therapeutic community - which all participants will receive - consists of group therapy (once a week), individual psychotherapy (once a week), counselling by social workers, psychiatric consultations, as well as sport-, art- and work-therapy. Daily life is organized according to principles of therapeutic community-based addiction treatment.

Held in the therapeutic community, the intervention will employ principles of cognitive-behavioural therapy (CBT) coupled with personalized recommendations for nicotine replacement. The Austrian Health Insurance standard for therapy will be guiding the program's content, which is tailored for inpatient clients. Specifically, the following interventions based on CBT techniques will be applied in the weekly group sessions consisting of 10 to 15 participants: Psychoeducation including information on tobacco addiction, health risks, advice on relapse prevention and the handling of craving, motivation building, behavioural observation.

Geen tussenkomst: Healthy controls

Control group with n=50 healthy adult subjects, examined at a single timepoint. No interventions will be administered in this arm.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Self-efficacy
Tijdsspanne: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period

Self-efficacy as a psychological variable and will be assessed by the Self-Efficacy Scale (SWE), a self-report instrument for measuring general optimistic self-confidence. It consists of 10 items and measures optimistic competence expectancy, i.e., confidence in solving difficult situations with one's own abilities.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period
General substance-related craving
Tijdsspanne: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Substance related craving will be assessed by the MaCS (Mannheim Craving Scale). consists of 12 items and four additional items and is rated on a 5- point Likert scale.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
Tobacco dependence
Tijdsspanne: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Tobacco dependence will be assessed by The Fagerström Test for Cigarette Dependence (formerly Fagerström Test for Nicotine Dependence; FTND). It consists of 6 categorically scaled items that assess the number of smoked cigarettes per day (CPD), compulsive use, and dependence intensity.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
Primary Affects
Tijdsspanne: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Primary Affects, as proposed by Jaak Panksepp will be assessed by the German Version of the Brief Affective Neuroscience Personality Scales including a LUST Scale (BANPS-GL), a self-report questionnaire.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
Metabolome
Tijdsspanne: From enrollment to the end of the 6-weeks treatment period.

Metabolome will be ascertained from blood via state-of-the-art NMR (nuclear magnetic resonance).

From enrollment to the end of the 6-weeks treatment period.
Gut microbiome
Tijdsspanne: From enrollment to the end of the 6-weeks treatment period.

Gut microbiome will be ascertained via 16s-rRNA sequencing from stool.

From enrollment to the end of the 6-weeks treatment period.
Smoking behaviour
Tijdsspanne: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Participants will be asked regarding their daily smoked cigarettes in the last two weeks (interval scaled). A second single item question will be, if participants have been completely abstinent from tobacco smoking in the last two weeks (dichotome).

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Psychiatric Symptoms
Tijdsspanne: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

For the evaluation of psychopathology, the ICD-10 Symptom Rating (ISR) questionnaire will be utilized. In accordance with the ICD-10, this self-assessment questionnaire, comprising 30 items, is designed to comprehensively assess the status and severity of mental disturbances. Symptoms of the six symptomatic patterns - depressive, anxiety, obsessive-compulsive, eating disorders, somatoform syndrome, and post-traumatic stress disorder - are assessed.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

5 mei 2025

Primaire voltooiing (Werkelijk)

18 september 2026

Studie voltooiing (Werkelijk)

18 september 2026

Studieregistratiedata

Eerst ingediend

23 januari 2025

Eerst ingediend dat voldeed aan de QC-criteria

27 januari 2025

Eerst geplaatst (Werkelijk)

31 januari 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

29 september 2026

Laatste update ingediend die voldeed aan QC-criteria

28 september 2026

Laatst geverifieerd

1 maart 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren